Trials / Completed
CompletedNCT00288925
Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment
Phase Ib/IIa, to Evaluate the Safety and Pharmacokinetics of Z-360 in Subjects With Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- Zeria Pharmaceutical · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety of two doses of Z-360 with Gemcitabine administration for subjects with unresectable advanced pancreatic cancer in order to determine the optimal dosage for PhaseII study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Z-360 |
Timeline
- Start date
- 2005-09-01
- Primary completion
- 2007-12-01
- First posted
- 2006-02-08
- Last updated
- 2009-06-01
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00288925. Inclusion in this directory is not an endorsement.